

A Guide to ICER's Public Meeting and How to Participate

Table of Contents

What are "Public Meetings"?

Why Does ICER Hold Public Meetings?

What's the Format of a Public Meeting?

How to Participate at a Public Meeting?

What's the Impact of Your Input?

What are "Public Meetings"?

The public meeting is a live-streamed Zoom webinar, usually lasting around 6 hours.

stakeholders together for a public discussion about fair pricing and fair insurance coverage for a new drug.

Patient perspectives are critical to this conversation, and patients help the voting councils (more information below) hear first-hand about the lived experience with their disease and treatments.



Why Does ICER Hold Public Meetings?

Public meetings are the culmination of ICER's drug review process and represent our attempt to bring decisions around drug pricing and patient access into the open. We believe patients, alongside other stakeholders, deserve an equal seat at the table to help guide decisions that impact their ability to afford and access treatments.



While patients have the opportunity to provide their written and verbal input throughout ICER's 8-month process, the public meeting is a unique opportunity to publicly represent their patient community and have their voice heard.

What's the Format of Public Meeting?

- **EVIDENCE PRESENTATION** ICER presents our findings (patient community insights, clinical and economic results) from the Evidence Report to an independent voting council.
- **PUBLIC COMMENTS** Patients and other stakeholders give 5-minute oral comments about their lived experience and thoughts on ICER's report.
- **VOTING SESSION** The voting council discusses the report findings and patient input, and they vote on different aspects of the drug under review.
- **POLICY ROUNDTABLE** A group of experts (including patients, clinicians, insurance representatives, and the manufacturer of the drug) share important insights on how to think about policy issues related to pricing, insurance coverage, and future research for the drug.

Who Are The Voting Councils?

ICER has three different independent voting councils made up of experts in:

- Patient Advocacy
 Health Economics
- Medicine
- Health Care Policy

These voting council members are not meant to represent specific diseases/conditions, but rather to use their health care expertise to provide guidance across all diseases and treatments. Importantly, the voting council is meant to serve as an unbiased group who can independently vote on the effectiveness and value of a new drug compared to drugs already in the market.







How to Participate at a Public Meeting?

ICER invites the patient community (patient advocacy groups, patients, and caregivers) to participate in different ways at our public meeting:

1

You can register and attend ICER's virtual public meeting for free and listen in as an <u>audience member</u>.

2

You can be invited as a patient expert on our panel to offer guidance on the Evidence Presentation and Voting Session and represent the patient voice during the Policy Roundtable.

3

You can request to provide a <u>5-minute</u> <u>oral comment</u> to share your lived experience and any feedback on ICER's report findings.

What's the Impact of Your Input?

Patient perspectives provided during the public meeting are **critical to guiding the voting council about how to think about the value of the new drug**, especially when important considerations are not currently measured in the clinical trial data. Your input can help highlight:

- The real-world stories about challenges with accessing the drugs that you may need
- What health outcomes and impacts matter most to you
- If a treatment has any benefits or risks that were not fully captured in a clinical trial
- Any additional information policymakers should know when figuring out a fair price and fair insurance coverage

Any input you provide during the public meeting and Policy Roundtable will help inform ICER's policy recommendations included in the final report version. We also include written summaries of your 5-minute oral comment in our final report.